VITA 34 (V3V) AI Stock Analysis

• Market Cap: €119.41M
• Dividend Yield: N/A
• Average Volume (3M): 2.47K
• Price to Earnings (P/E): 27.3
• Beta (1Y): 0.19
• Revenue Growth: 11.30%
• EPS Growth: -3316.77%
• Country: DE
• Employees: 783
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Care Facilities
• EPS (TTM): 0.04
• Shares Outstanding: 17,640,104
• 10 Day Avg. Volume: 3,813
• 30 Day Avg. Volume: 2,470
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €7.00
• Price Target Upside: 0.72% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: €7.00 ▲(0.72% Upside)

The overall stock score of 50 reflects significant financial challenges, including ongoing losses and high leverage, which are major concerns. However, positive technical indicators provide some optimism, suggesting potential short-term price momentum. The negative P/E ratio and lack of dividend yield weigh on the valuation, limiting the stock's attractiveness.

VITA 34 Business Overview & Revenue Model

Company Description

VITA 34 (V3V) is a leading company in the field of stem cell banking and regenerative medicine, specializing in the collection, processing, and storage of stem cells derived from umbilical cord blood and tissue. The company operates primarily in the healthcare sector, offering its services to expectant parents and healthcare providers. VITA 34's core products include private and public stem cell storage solutions, as well as related services that support the use of stem cells in medical treatments and research.

How the Company Makes Money

VITA 34 generates revenue primarily through its stem cell banking services, which include the collection, processing, and long-term storage of umbilical cord blood and tissue. The company charges fees for initial service packages, which encompass the collection and processing of stem cells at the time of birth, as well as ongoing annual storage fees. Additionally, VITA 34 may earn income from partnerships with healthcare institutions and research organizations, as well as from the sale of stem cell-related products and services. Collaborations with hospitals and clinics to promote their banking services can also contribute to revenue growth, alongside potential revenue from licensing agreements or research funding.

VITA 34 Financial Statement Overview

Summary

VITA 34 is experiencing financial difficulties with ongoing losses, high leverage, and weak cash flow generation. The income statement shows modest revenue growth but negative profitability metrics. The balance sheet indicates significant leverage with a high debt-to-equity ratio, and cash flow analysis reveals liquidity concerns with a significant decline in free cash flow.

Income Statement

VITA 34's income statement reflects a challenging financial position. The company has experienced modest revenue growth, with a TTM (Trailing-Twelve-Months) revenue growth rate of 2.35%. However, profitability metrics are concerning, with negative net profit and EBIT margins indicating ongoing losses. The gross profit margin has improved slightly to 27.61% in the TTM, but the company remains unprofitable, which is a significant weakness.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio of 1.50, indicating significant leverage and potential financial risk. Return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is relatively low, suggesting limited financial stability. These factors highlight the company's financial vulnerability.

Cash Flow

Cash flow analysis reveals a significant decline in free cash flow, with a growth rate of -79.51% in the TTM. The operating cash flow to net income ratio is low, indicating challenges in converting earnings into cash. The free cash flow to net income ratio is also weak, suggesting limited cash generation relative to losses. These metrics highlight cash flow constraints and liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	87.73M	82.18M	77.06M	68.94M	28.42M	20.07M
Gross Profit	24.23M	20.65M	28.24M	2.73M	12.44M	11.66M
EBITDA	2.80M	-443.00K	5.81M	-18.34M	949.00K	5.01M
Net Income	-9.95M	-12.14M	-1.86M	-27.39M	-3.93M	1.45M
Balance Sheet
Total Assets	157.42M	152.74M	158.36M	151.51M	177.95M	58.46M
Cash, Cash Equivalents and Short-Term Investments	11.50M	18.46M	17.42M	18.23M	35.26M	10.52M
Total Debt	19.67M	18.10M	21.57M	28.18M	32.32M	5.30M
Total Liabilities	145.65M	139.83M	135.58M	135.66M	136.00M	28.93M
Stockholders Equity	13.15M	14.13M	23.56M	16.50M	43.07M	29.55M
Cash Flow
Free Cash Flow	771.00K	5.46M	5.06M	-10.92M	467.00K	3.33M
Operating Cash Flow	4.59M	8.65M	9.15M	-4.49M	2.73M	3.98M
Investing Cash Flow	-7.68M	-3.08M	-3.57M	-5.81M	24.87M	-252.00K
Financing Cash Flow	45.00K	-6.09M	-5.09M	-6.27M	-4.70M	-2.43M

VITA 34 Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:V3V, the sentiment is Positive. The current price of 6.95 is above the 20-day moving average (MA) of 6.24, above the 50-day MA of 5.42, and above the 200-day MA of 4.43, indicating a bullish trend. The MACD of 0.52 indicates Negative momentum. The RSI at 63.94 is Neutral, neither overbought nor oversold. The STOCH value of 51.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:V3V.

VITA 34 Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
93M1	73 Outperform	€73.85M	2.31	12.12%	6.84%	-15.43%	8.45%
LIK	69 Neutral	€118.80M	25.26	23.66%	―	0.21%	7.53%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
V3V	50 Neutral	€119.41M	27.28	-53.67%	―	11.30%	-3316.77%
MAK	43 Neutral	€23.70M	―		―	11.43%	7.72%
HAEK	―	€53.15M	―		―	―	―
JTH0	―	€23.40M	11.43		―	―	―